DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* DIAXONHIT *


 

1997 - IDF
Paris
www.diaxonhit.com

 

Discovery, Diagnostics
(also, Discovery, Drugs)
Key words: RNA splicing, Gene profiling technology, Cancer, Alzheimer
Mission: to leverage on alternative RNA splicing, the process by which a single gene can lead to several proteins in the fields of drug discovery, diagnostics and biochips and to sell proprietary gene profiling technology named Datas in order to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease
Clients: Pharmaceutical industry (own development up to phase II)
infofi@exonhit.com

Age: 19 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Maurel (Loïc) [M.D., ex-Debiovision, Novartis, Rhône Poulenc Rorer]
Sc.Dir.-CSO: Pando (Matthew) [Ph.D. molecular biology]
Fin.Dir.-CFO: Duchesne de Lamotte (Hervé) [MBA, Ms (MIT), ex-Stanford Research Institute, AT Kearney France, IDM, Cirrus Finance Management]
C.O.O.: (Diagnostics Division) Barber (Isabelle) [Ph.D. organic chemistry, ex-Isis Pharmaceuticals, Genset, Ortho Clinical Diagnostics (J&J)]
C.O.O.: (Therapeutic Division) Pando (Matthew) [Ph.D. molecular biology]
BusDev:
Comm.Dir.: Hoff (Corinne) [ex-Nicox, Aventis, Novartis)]
Financers (Hist.): CDC Innovation, Sofinnova, Oxford Bioscience Partners, AGF P.E., BNP P.E., Dresdner Kleinwort, Danske Bank, LCF Ed. de Rotschild, Sudinnova, Biomérieux (5.8%, end 2007), Public

Turnover (M€) : 4.8 (2009), 4.0 (2008), 5.2 (2007)
Total funding (M€) : 106.9
Last funding (M€) : 4.4
Focus : Genome
Position : Trade
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2012 .12 Acquisition of Ingen, the leading independent distributor of in-vitro diagnostics in the French market with global company's name change from Exonhit to Diaxonhit ACQ+ [15 years]
2012 .11 Round-financing : 4.4 M€ through private investors (new shares) RFIN [15 years]
2012 .07 Clinical assessment completed for AclarusDx, a blood test that detects Alzheimer's disease specific biomarkers, in France and USA CLIN [14 years]
2011 .10 Partnering R&D agreement with Pfizer to identify Alzheimer’s disease biomarkers R&D [13 years]
2011 .03 Clinical validation for EHT Dx14 (first phase), a new transcriptomic signature allowing to differentiate, at molecular level, benign breast tumors from malignant tumors CLIN [13 years]
2010 .06 Round-financing : 1.43 M€ through TEPA-induced private investors RFIN [12 years]
2010 .04 Acquisition of oncology-focused RedPath Integrated Pathology (USA) to accelerate growth in molecular diagnostics (total : US$ 32 Millions), which has been mutually terminated in October 2010 ACQ+ [12 years]
2010 .03 Licensing-out to Allergan and BMS of EHT/AGN001 (a compound already in long term contract with Allergan), with upfront payment of 4 MUS$ LICOUT [12 years]
2009 .12 Public offering (4th) on Alternext : 15.6 M€ PBO [12 years]
2009 .11 Launch of AclarusDx, first diagnostic test in Alzheimer available as a Research Use Only product for Pharma industry (first step) MKTG [12 years]
2009 .09 Clinical trial (phase IIa) for EHT 0202 in Alzheimer's disease (completed) CLIN [11 years]
2009 .07 Round-financing : 1.45 M€ through the exercise of warrant with existing investors RFIN [11 years]
2009 .03 Proof-of-concept for SpliceArray platform for cancer diagnostic, evidence by I.G.R. (publication in Lancet Oncology) R&D [11 years]
2008 .06 Nomination : Loïc Maurel, as CEO ORGN [10 years]
2008 .04 Nomination : Philippe Rousseau as interim CEO after founders' resignation ORGN [10 years]
2007 .06 Public offering (3rd) on Alternext : 3.4 M€ PBO [9 years]
2006 .11 5th round-financing : 13.5 M€, in convertible bonds RFINE [9 years]
2006 .04 Public offering (2nd) on Alternext : 6.5 M€ PBO [8 years]
2005 .11 Listing on Alternext : 7.3 M€ PBO [8 years]
2004 .02 4th round-financing : 8.3 M€ in convertible bonds RFIND [6 years]
2001 .12 Licensing-out to Biomérieux (diagnostics) LICOUT [4 years]
2001 .12 3rd round-financing : 30.0 M€, by Dresdner Kleinwort, Danske Bank, LCF E. de Rothschild, Sudinnova, and previous shareholders RFINC [4 years]
2001 .11 Licensing-out to Allergan (drugs) LICOUT [4 years]
2001 .01 Set-up of US subsidiary in Maryland ORGC [3 years]
2000 .09 2nd round-financing : 14.0 M€, by AGF P.E. and BNP P.E. RFINB [2 years]
1998 .06 1st round-financing : 3.7 M€, by CDC Innovation, Sofinnova, Oxford Bioscience Partners (also, 0.8 M€, by ANVAR) RFINA [0 year]
1997 .11 Company founded by Bruno Tocqué [ex-Rhône Poulenc Rorer], Laurent Bracco [ex-RPR], Fabien Schweighoffer [ex-RPR] ORGF [0 year]

Actualisation / Updating: 20-Feb-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende